Vimarsana
Biggest News Aggregation in the World

Page 36 - Robert Blum News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Robert Blum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Robert Blum Today - Breaking & Trending Today

Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation - Vimarsana News

Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation

Published: January 23, 2023

Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com
Related Topics:
Cadrenal TherapeuticsprospectusRobert BlumQuang PhamMatthew SzotSean PokorneyLytham PartnersDrug AdministrationCadrenal Therapeutics IncProfessor Of Medicine At Duke UniversityFast TrackChief Executive OfficerAssistant ProfessorDuke UniversityPrimary InvestigatorAccelerated ApprovalPriority ReviewNew Drug ApplicationOrphan Drug DesignationChronic Kidney DiseaseCadrenal Therapeutics ProspectusCadrenal TherapeuticsAdrenal Therapeutics Nasdaq Cvkd Granted Fda Fast Track Designation For Tecarfarin Prevention Of Systemic Thromboembolism Cardiac Origin In Patients With End Stage Renal Disease And Atrial Fibrillation
Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) - Vimarsana News

Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)

Published: January 20, 2023

/PRNewswire/ -- Cadrenal Therapeutics, Inc., a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with...

Source: prnewswire.com
Related Topics:
United StatesKeith MooreRobert BlumMatthew SzotPrnewswire Cadrenal Therapeutics IncExchange CommissionBoustead SecuritiesLytham PartnersCadrenal Therapeutics IncNasdaq Capital MarketEquity Capital MarketsChronic Kidney DiseaseCadrenal TherapeuticsUnderwriter Inquiries
Lightwave Logic CEO Dr. Michael Lebby to Participate in the Laser Focus World Executive Forum - Vimarsana News

Lightwave Logic CEO Dr. Michael Lebby to Participate in the Laser Focus World Executive Forum

Published: January 17, 2023

/PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic polymers to transmit data at...

Source: prnewswire.com
Related Topics:
United StatesSan FranciscoMichael LebbyLucasa ZimmermanDavid Piehler DellJose Pozo OpticaMz GroupPanel DiscussionPrnewswire Lightwave Logic IncLaser Focus World Executive ForumLightwave Logic IncIntercontinental HotelPeter Winzer Nubis CommunicationsChief Executive OfficerFocus World Executive ForumEnabling Silicon PhotonicsJose PozoDavid PiehlerDell TechnologiesPeter WinzerNubis CommunicationsRobert BlumSilicon PhotonicsLightwave LogicPrivate Securities Litigation Reform Act
Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023 - Vimarsana News

Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023

Published: January 17, 2023

/PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving...

Source: prnewswire.com
Related Topics:
New YorkUnited StatesRobert BlumAnatoly DritschiloGeorgetown UniversityLytham PartnersPrnewswire Shuttle Pharmaceuticals Holdings IncCompany Quarterly Report On FormShuttle Pharmaceuticals Holdings IncShuttle PharmaceuticalsPharmaceuticals HoldingsChief Executive OfficerShuttle PharmaOpening BellNasdaq Marketsite TowerNew York CityMedical CenterQuarterly ReportShuttle Pharmaceuticals Holdings
Stock Day Media: Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast - Vimarsana News

Stock Day Media: Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

Published: January 17, 2023

Phoenix, Arizona--(Newsfile Corp. - January 17, 2023) - The Stock Day Podcast welcomed Acasti Pharma, Inc. (NASDAQ: ACST), a late-stage specialty pharma company with drug delivery technologies and drug

Source: finanznachrichten.de
Related Topics:
United StatesRobert BlumJan DalviseEverett JollyArizona Newsfile CorpExchange CommissionAcasti Pharma IncLytham PartnersSecurities ExchangeRegulation Services ProviderStock Day PodcastAcasti PharmaJand AlviseStock DaySubarachnoid HemorrhageStock Day MediaOrphan Drug DesignationSecurities Litigation Reform ActSecurities ActSecurities Exchange Act